Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.

  1. December 13, 2022

    Teva, Apotex Win Ax Of Patents In Sleep Drug Suit

    A Delaware federal judge on Tuesday wiped out four patents that Vanda Pharmaceuticals asserted against rivals Teva and Apotex in litigation over a planned generic version of sleep disorder drug Hetlioz, finding that they are invalid as obvious.

  2. March 24, 2022

    IP Forecast: Fed. Circ. To Mull Arthrex's Latest USPTO Fight

    Arthrex will argue next week that the Federal Circuit must undo the Patent Trial and Appeal Board's invalidation of its suture patent because the patent office’s interim leader lacks the power to review that ruling under a U.S. Supreme Court decision involving the company. Here's a look at where that case stands — plus all the other major intellectual property matters on deck in the coming week.

  3. January 14, 2022

    Vanda Settles Sleep Drug Patent Claims Against MSN Pharma

    Vanda Pharmaceuticals Inc. announced the settlement Friday of a multiyear patent dispute with MSN Pharmaceuticals and Impax Laboratories, based in part on a future licensing agreement with MSN and Impax covering Vanda's Hetlioz product, used for some types of sleep-wake disorders.